LOS ANGELES, Sept. 21, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE:VSI) for possible violations of federal securities laws from March 1, 2017 through August 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the October 27, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements, and/or failed to disclose: that the Company’s retail segment was continuing to dramatically decline; that the Company’s ongoing “reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment, and it was not properly recognizing that impairment charge; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news was announced, shares of Vitamin Shoppe declined in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/


Italy Fines Apple €98.6 Million Over App Store Dominance
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 



